Navigation Links
Stem Cell Treatment For Children With Brain Injury To Be Initiated

It has been proposed to initiate a novel clinical trial to assess the clinical benefits and safety of stem cell based therapy for treatment of traumatic brain injury in children at the University of Texas. // The U.S. Food and Drug Administration (FDA) and the university’s Committee for the Protection of Human Subjects (CPHS) have already approved the proposal.

The fact that stem cells derived from bone marrow can drift to an injured area in the brain followed by differentiation into neurons and induce repair in animal models has offered a new hope for the present study. The study would be based on the utilization of bone marrow derived stem cells derived from the patient, eliminating the ethical concerns regarding the use of embryonic stem cells.

"There is no reparative treatment for traumatic brain injury. All we can do now is try to prevent secondary damage by relieving pressure on the brain caused by the initial injury, " said principal investigator Charles Cox.

The bone, muscle and other organs have an inherent capacity to heal following an injury. The brain however has very poor regenerative capacity, accounting for the high mortality and functional disability following traumatic brain injury. More that 15 to 25% of children suffering severe traumatic brain injury die. Those who survive face a life long disability even in case of a moderate injury.

The I phase of the clinical trial would be directed towards establishing the safety of the treatment modality while the secondary objective would be observation of the potential therapeutic effects. Ten head injury patients with between 5 and 14 years of age would be recruited for the study based upon the inclusion and exclusion criteria. Followed by initial treatment and evaluation, the parents of the injured child would be approached regarding participation in the clinical trial.

After obtaining a written informed consent, progenitor stem cells from the bone marrow in the hip region would be extracted. This would be processed to obtain two different types of cells; mesenchymal stem cells capable of differentiating into bone, cartilage, fat cells, neurons and hematopoietic stem cells capable of differentiating into blood cells.

This would be followed by processing of the mesenchymal stem cells at Baylor College of Medicine and introduction into the injured child by an intra-venous injection. The entire process would be accomplished within 48 hours of the injury.

A critical monitoring of the injured children would be taken up. In addition, tests to assess the function of the brain would be carried out at end of 1 and 6 months following the procedure. The results obtained would be compared to the existing data on other similar children with brain injury.

Even marginal improvement could mean a great deal to someone who suffers a brain injury. "It could be the difference between being able to recognize your loved ones and not being able to, or between doing things for yourself or having to rely on others. That would be a huge impact on families and on society," Cox said.

Depending on the results obtained, further studies would be carried out on a larger scale. One of the main advantages of the present study is that the possibility of an immune rejection is unlikely, as the study participants would be receiving their own cells.


Related medicine news :

1. Advances in Treatment of Cataracts
2. Recommendations for Treatment of Blood Pressue
3. Treatment for Menieres disease
4. Treatment for pre-menstrual syndrome is ineffective
5. Better Treatment for obesity
6. Gene Treatment for Heart Disease
7. More People Seeking Treatment for Depression
8. Focused Treatment For Childhood Cancer
9. Inadequate Drug Treatment For Youth
10. FDA Approves New surgery Treatment for Farsightedness
11. Treatment of antibiotics ineffectual in bronchitis
Post Your Comments:

(Date:11/30/2015)... (PRWEB) , ... November 30, ... ... (AIS) is pleased to announce the speakers for “Value-Based Payer-Provider Partnerships: Three ... learned from three innovative value-based care arrangements: Essentia Health and UCare, MissionPoint ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... DataTrade Solutions Inc., a Healthcare IT consulting, development and support company. The purchase ... technical experience available within DataTrade to extend the services currently provided by Healthjump. ...
(Date:11/30/2015)... (PRWEB) , ... November 30, ... ... ), a leading provider of enterprise Time and Attendance/Workforce Management cloud-based ... in the Microsoft Partner Program with competencies in the Application Development, demonstrating ...
(Date:11/30/2015)... , ... November 30, 2015 , ... ... 2016. In 2016, expected coding changes are likely to include new codes for ... It’s not easy to understand the effects of code changes in musculoskeletal, radiology ...
(Date:11/29/2015)... Birmingham, Lake Orion, Clarkston, Metamora, Michigan (PRWEB) , ... ... ... Women's Excellence is once again accredited by the American Institute ... peer review process that allows practices to demonstrate that they meet or ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... Nov. 30, 2015  Novartis will demonstrate the strength ... th American Society of Hematology (ASH) Annual Meeting. ... as well as supportive care, including key findings in ... cell therapies. The ASH Annual Meeting will be held ... Novartis Oncology . "We will be presenting ...
(Date:11/30/2015)... BOSTON , November 30, 2015 ... new medicines directed at up to 10 G protein-coupled ... PFE ) to research and develop potential new ... (GPCR) targets across multiple therapeutic areas. --> ... and development company and wholly-owned subsidiary of Sosei Group ...
(Date:11/30/2015)... , November 30, 2015 ... or the "Company") announced today that it was informed by ... and Drug Safety (MFDS) has approved its Exablate Neuro ... --> --> Insightec,s Exablate ... treatment alternative that combines two technologies: Focused Ultrasound, which ...
Breaking Medicine Technology: